1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bachem Holding AG Class B

Bachem Holding AG Class B

82.55
CHF
-1.60
(-1.90%)
5.67BMarket Cap
Mar 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.53
2.72
3.08
3.49
3.85
4.16
4.53
5.74
7.1
7.21
7.73
8.07
9.27
- -
Basic EPS, GAAP
0.35
0.43
0.47
0.61
0.62
0.69
0.78
1.12
1.62
1.37
1.5
1.6
1.98
- -
Free Cash Flow per Basic Share
0.55
0.47
0.53
-0.16
-0.22
-0.18
0.49
0.66
-0.27
-0.67
-0.25
-1.84
-0.77
- -
Dividend per Share
0.3
0.35
0.25
0.3
0.35
0.4
0.4
0.6
0.29
0.7
0.75
0.8
0.41
- -
Book Value per Share
4.98
5.16
5.22
5.39
5.51
5.66
6.4
6.8
15.2
15.87
17.61
18.55
19.46
19.27
Tangible Book Value per Share
4.84
5.04
5.08
5.25
5.32
5.46
6.21
6.61
15.02
15.68
17.43
18.27
19.09
18.86
Basic Weighted Avg Shares
68
68
68
68
68
68
69
70
71
74
75
75
75
75
Sales/Revenue/Turnover
171
184
209
236
262
283
314
402
503
532
577
605
695
- -
Operating Margin (%)
17.25
18
18.45
19.05
18.68
19.4
19.88
24.05
25.62
23.93
22.41
21.98
24.07
- -
Depreciation Expense
18
19
18
20
21
23
25
26
28
33
37
43
47
- -
Net Income, GAAP
24
29
32
41
42
47
54
78
115
101
112
120
149
- -
Effective Tax Rate (%)
18.32
20.03
14.59
10.2
13.64
14.63
10.28
14.18
12.71
10.16
9.94
11.07
4.86
- -
Profit Margin (%)
13.83
15.8
15.26
17.42
15.97
16.51
17.27
19.42
22.79
18.93
19.38
19.87
21.41
- -
Working Capital
148
161
148
126
115
111
227
215
699
596
677
542
321
312
LT Debt
- -
- -
- -
- -
- -
- -
60
- -
- -
- -
- -
- -
- -
- -
Total Equity
336
349
353
365
374
384
448
476
1,121
1,170
1,321
1,391
1,458
1,444
Return on Invested Capital (%)
6.19
7.5
8.69
9.98
9.68
9.28
10.23
16.01
13.86
9.84
9.27
8.65
11.08
- -
Return on Capital (%)
6.26
7.79
8.62
10.46
9.45
9.37
10.01
15.21
14.22
8.71
8.98
8.87
10.47
- -
Return on Common Equity (%)
7.05
8.48
9.06
11.47
11.3
12.3
13.02
16.91
14.36
8.79
8.98
8.87
10.44
- -

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
75
Market Capitalization
4,348
4,489
5,669

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
711
727
829
Cash, Cash Equivalents & STI
29
31
52
Accounts Receivable, Net
174
179
174
Inventories
483
494
577
Total Current Liabilities
292
405
517
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.43%
32.61%
4.83%
Free Cash Flow
9.05%
108.21%
-58.19%
Net Income, GAAP
17.97%
15.41%
23.74%
Sales/Revenue/Turnover
13.03%
11.82%
14.84%
Total Cash Common Dividend
17.22%
13.51%
-48.77%

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
605
2025
- -
- -
695
2026
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.6
2025
- -
- -
1.98
2026
- -
- -
- -

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.8
2025
- -
- -
0.41
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Anne-Kathrin Stoller
Full Time Employees
2,511
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hauptstrasse 144 Bubendorf BL Switzerland 4416
IPO Date
Jun 29, 2001
Website
bachem.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bachem Holding AG Bachem Holding AG is a leading innovation-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacture of peptides and oligonucleotides for pharmaceutical and biotechnology companies worldwide. Founded in 1971 and headquartered in Bubendorf, Switzerland, the company provides a comprehensive portfolio of products and services, including catalog peptides, amino acid derivatives and biochemicals for research purposes; custom peptide synthesis and oligonucleotides for clinical development; generic active pharmaceutical ingredients (APIs) and commercial-scale GMP manufacturing of new chemical entities (NCEs); as well as services such as CMC development, project management and process optimization under the Bachem and Clinalfa brands. Bachem operates internationally through manufacturing sites in Bubendorf and Vionnaz (Switzerland), Torrance and Vista (USA), St. Helens (UK), and sales offices in Europe, North America and Asia, serving research, diagnostic, cosmetic and therapeutic markets across these regions. Recent developments include securing a CHF 1 billion peptide supply contract spanning 2025-2029 with a major client, enabling capacity expansions at existing sites including a large-scale facility in Bubendorf and high-volume production in Vista; planning a new manufacturing site in Eiken, Switzerland, with construction applications in 2025; reporting strong first-half 2025 sales growth prompting an upward revision of full-year guidance to 13-18% in local currencies; and ongoing investments in its global network to support oligonucleotide and peptide production amid rising demand.

Company News

Company News APIChatGPT